WO1998022493A3 - DERIVES DE N-(ARYL/HETEROARYL) AMINOACIDE, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET PROCEDES PERMETTANT D'INHIBER LA LIBERATION DE PEPTIDE β AMYLOIDE ET/OU SA SYNTHESE A L'AIDE DE CES COMPOSES - Google Patents

DERIVES DE N-(ARYL/HETEROARYL) AMINOACIDE, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET PROCEDES PERMETTANT D'INHIBER LA LIBERATION DE PEPTIDE β AMYLOIDE ET/OU SA SYNTHESE A L'AIDE DE CES COMPOSES Download PDF

Info

Publication number
WO1998022493A3
WO1998022493A3 PCT/US1997/018704 US9718704W WO9822493A3 WO 1998022493 A3 WO1998022493 A3 WO 1998022493A3 US 9718704 W US9718704 W US 9718704W WO 9822493 A3 WO9822493 A3 WO 9822493A3
Authority
WO
WIPO (PCT)
Prior art keywords
synthesis
pharmaceutical compositions
compounds
amyloid peptide
methods
Prior art date
Application number
PCT/US1997/018704
Other languages
English (en)
Other versions
WO1998022493A2 (fr
Inventor
James E Audia
Beverly K Folmer
Varghese John
Lee H Latimer
Jeffrey S Nissen
Warren J Porter
Eugene D Thorsett
Jing Wu
Original Assignee
Athena Neurosciences Inc
Lilly Co Eli
James E Audia
Beverly K Folmer
John Verghese
Lee H Latimer
Jeffrey S Nissen
Warren J Porter
Eugene D Thorsett
Jing Wu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athena Neurosciences Inc, Lilly Co Eli, James E Audia, Beverly K Folmer, John Verghese, Lee H Latimer, Jeffrey S Nissen, Warren J Porter, Eugene D Thorsett, Jing Wu filed Critical Athena Neurosciences Inc
Priority to IL12947797A priority Critical patent/IL129477A0/xx
Priority to BR9714358A priority patent/BR9714358A/pt
Priority to JP52364998A priority patent/JP2001519769A/ja
Priority to EP97950576A priority patent/EP0942923A2/fr
Priority to CA002270876A priority patent/CA2270876A1/fr
Priority to AU53543/98A priority patent/AU5354398A/en
Priority to NZ335157A priority patent/NZ335157A/xx
Priority to HU0001383A priority patent/HUP0001383A3/hu
Publication of WO1998022493A2 publication Critical patent/WO1998022493A2/fr
Publication of WO1998022493A3 publication Critical patent/WO1998022493A3/fr
Priority to NO992426A priority patent/NO992426L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention a trait à des composés inhibant la libération de peptide β-amyloïde et ou sa synthèse et, de ce fait, se révélant utiles s'agissant de traiter la maladie d'Alzheimer. Elle a également trait à des compositions pharmaceutiques contenant un composé inhibant la libération de peptide β-amyloïde et ou sa synthèse ainsi qu'à des méthodes de traitement de la maladie d'Alzheimer, tant au plan prophylactique que thérapeutique, ces méthodes faisant intervenir lesdites compositions pharmaceutiques.
PCT/US1997/018704 1996-11-22 1997-11-20 DERIVES DE N-(ARYL/HETEROARYL) AMINOACIDE, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET PROCEDES PERMETTANT D'INHIBER LA LIBERATION DE PEPTIDE β AMYLOIDE ET/OU SA SYNTHESE A L'AIDE DE CES COMPOSES WO1998022493A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
IL12947797A IL129477A0 (en) 1996-11-22 1997-11-20 N-(aryl/heteroaryl)amino acid derivatives pharmaceutical compositions comprising same and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
BR9714358A BR9714358A (pt) 1996-11-22 1997-11-20 Derivados de n- (arila/heteroarila) amino ácido,composições farmacêuticas compreendendo os mesmos, e métodos para a inibição de liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos
JP52364998A JP2001519769A (ja) 1996-11-22 1997-11-20 Ｎ―（アリール／ヘテロアリール）アミノ酸誘導体、その医薬組成物および該化合物を用いたβ―アミロイドペプチドの放出および／またはその合成を阻害する方法
EP97950576A EP0942923A2 (fr) 1996-11-22 1997-11-20 DERIVES DE N-(ARYL/HETEROARYL) AMINOACIDE, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET PROCEDES PERMETTANT D'INHIBER LA LIBERATION DE PEPTIDE $g(b) AMYLOIDE ET/OU SA SYNTHESE A L'AIDE DE CES COMPOSES
CA002270876A CA2270876A1 (fr) 1996-11-22 1997-11-20 Derives de n-(aryl/heteroaryl) aminoacide, compositions pharmaceutiques les contenant et procedes permettant d'inhiber la liberation de peptide .beta. amyloide et/ou sa synthese al'aide de ces composes
AU53543/98A AU5354398A (en) 1996-11-22 1997-11-20 N-(aryl/heteroaryl) amino acid derivatives, pharmaceutical compositions compri sing same, and methods for inhibiting beta-amyloid peptide release and/or it s synthesis by use of such compounds
NZ335157A NZ335157A (en) 1996-11-22 1997-11-20 N-(aryl/heteroaryl) amino acid derivatives and methods for inhibiting beta-amyloid peptide release or its synthesis
HU0001383A HUP0001383A3 (en) 1996-11-22 1997-11-20 N-(aryl/heteroaryl) amino acid derivatives, pharmaceutical compositions comprising same and their use
NO992426A NO992426L (no) 1996-11-22 1999-05-20 N-(aryl/heteroaryl)aminosyrederivater, farmas°ytiske sammensetninger som omfatter det samme, og metoder for inhibering av <beta>-amyloidpeptid frigivelse og/eller dens syntese ved bruk av slike forbindelser

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75533496A 1996-11-22 1996-11-22
US08/755,334 1996-11-22

Publications (2)

Publication Number Publication Date
WO1998022493A2 WO1998022493A2 (fr) 1998-05-28
WO1998022493A3 true WO1998022493A3 (fr) 1998-07-23

Family

ID=25038718

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/018704 WO1998022493A2 (fr) 1996-11-22 1997-11-20 DERIVES DE N-(ARYL/HETEROARYL) AMINOACIDE, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET PROCEDES PERMETTANT D'INHIBER LA LIBERATION DE PEPTIDE β AMYLOIDE ET/OU SA SYNTHESE A L'AIDE DE CES COMPOSES

Country Status (13)

Country Link
EP (1) EP0942923A2 (fr)
JP (1) JP2001519769A (fr)
CN (1) CN1237978A (fr)
AU (1) AU5354398A (fr)
BR (1) BR9714358A (fr)
CA (1) CA2270876A1 (fr)
HU (1) HUP0001383A3 (fr)
ID (1) ID22275A (fr)
IL (1) IL129477A0 (fr)
NO (1) NO992426L (fr)
NZ (1) NZ335157A (fr)
TR (1) TR199901132T2 (fr)
WO (1) WO1998022493A2 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ525513A (en) 1998-08-07 2004-09-24 Pont Pharmaceuticals Du Succinoylamino lactams as inhibitors of Abeta protein production
HRP990246A2 (en) 1998-08-07 2000-06-30 Du Pont Pharm Co Succinoylamino benzodiazepines as inhibitors of a beta protein production
AU6278099A (en) 1998-09-30 2000-04-17 Elan Pharmaceuticals, Inc. Biological reagents and methods for determining the mechanism in the generation of beta-amyloid peptide
US6737038B1 (en) 1998-11-12 2004-05-18 Bristol-Myers Squibb Company Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
AU778005B2 (en) 1998-12-24 2004-11-11 Bristol-Myers Squibb Pharma Company Succinoylamino benzodiazepines as inhibitors of Abeta protein production
US6503902B2 (en) 1999-09-13 2003-01-07 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production
US6960576B2 (en) 1999-09-13 2005-11-01 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production
AU7997600A (en) 1999-10-08 2001-04-23 Du Pont Pharmaceuticals Company Amino lactam sulfonamides as inhibitors of abeta protein production
JP2003523345A (ja) 2000-02-17 2003-08-05 ブリストル−マイヤーズ スクイブ ファーマ カンパニー Ａβタンパク質産生の阻害剤としてのスクシノイルアミノ炭素環および複素環
JP2004508289A (ja) 2000-04-03 2004-03-18 デュポン　ファーマシューティカルズ　カンパニー Ａβタンパク質産生の阻害剤としての環状ラクタム
EP1268433A1 (fr) 2000-04-03 2003-01-02 Bristol-Myers Squibb Pharma Company Lactames cycliques utilises comme inhibiteurs de la production de la proteine beta-amyloide
EP1289966A1 (fr) 2000-04-11 2003-03-12 Bristol-Myers Squibb Pharma Company LACTAMES SUBSTITUES UTILISES EN TANT QU'INHIBITEURS DE PRODUCTION DE PROTEINE A$g(b)
US6878363B2 (en) 2000-05-17 2005-04-12 Bristol-Myers Squibb Pharma Company Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
EP1268450A1 (fr) 2000-06-01 2003-01-02 Bristol-Myers Squibb Pharma Company Lactames substitues par des succinates cycliques en tant qu'inhibiteurs de la production de la proteine beta
US6432944B1 (en) 2000-07-06 2002-08-13 Bristol-Myers Squibb Company Benzodiazepinone β-amyloid inhibitors: arylacetamidoalanyl derivatives
SI1334091T1 (sl) 2000-08-24 2013-01-31 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Derivati tioflavina in njihova uporaba pri diagnozi in terapiji pri Alzheimerjevi bolezni
US7270800B2 (en) 2000-08-24 2007-09-18 University Of Pittsburgh Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
BR0116063A (pt) 2000-12-13 2004-08-03 Wyeth Corp Inibidores de sulfonamida heterocìclica da produção de beta amilóide e seus usos
US6657070B2 (en) 2000-12-13 2003-12-02 Wyeth Production of chirally pure α-amino acids and N-sulfonyl α-amino acids
CH698246B1 (de) * 2001-12-20 2009-06-30 Hoffmann La Roche Test zur Identifizierung von Inhibitoren von Beta-Sekretasen.
DE10306202A1 (de) * 2003-02-13 2004-08-26 Grünenthal GmbH Arzneimittel enthaltend substituierte 2-Aryl-Aminoessigsäure-Verbindungen und/oder substituierte 2-Heteroaryl-Aminoessigsäure-Verbindungen
RU2440995C2 (ru) * 2003-03-14 2012-01-27 Юнивесити Оф Питсбэг Производные бензотиазола, фармацевтическая композиция, обладающая свойством связывать амилоид, и способ детекции отложений амилоида у млекопитающего
MXPA05010368A (es) 2003-03-31 2005-11-17 Wyeth Corp Sulfonamidas heterociclicas que contienen fluor- y trifluoroalquilo como inhibidores de la produccion beta amiloide y derivados de las mismas.
JP4220548B2 (ja) 2003-06-05 2009-02-04 エラン ファーマシューティカルズ，インコーポレイテッド アシル化されたアミノ酸・アミジルピラゾール、および関連化合物
US8236282B2 (en) 2003-08-22 2012-08-07 University of Pittsburgh—of the Commonwealth System of Higher Education Benzothiazole derivative compounds, compositions and uses
EP1709003B1 (fr) 2004-01-16 2009-09-23 Wyeth Inhibiteurs a base de sulfonamides heterocycliques de la production des beta-amyloides contenant un azole
JP4805909B2 (ja) 2004-03-03 2011-11-02 スミスクライン ビーチャム コーポレーション 選択的アンドロゲン受容体モジュレーターとしてのアニリン誘導体
JP2008536868A (ja) * 2005-04-15 2008-09-11 スミスクライン・ビーチャム・コーポレイション シアノアリールアミン
CN100999546B (zh) * 2007-01-11 2010-08-11 清华大学 具有含氮杂环修饰的多肽类化合物及其应用
WO2012172449A1 (fr) 2011-06-13 2012-12-20 Pfizer Inc. Lactames convenant comme inhibiteurs des bêta-sécrétases
CN111777571B (zh) * 2020-06-28 2023-07-11 武汉药明康德新药开发有限公司 一种手性2-氨基-3 -(1,3-苯并噻唑-2-基)丙酸盐酸盐的合成方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009838A1 (fr) * 1993-10-01 1995-04-13 Merrell Pharmaceuticals Inc. INHIBITEURS DE LA PRODUCTION DE PROTEINES DE β-AMYLOIDE
WO1996020725A2 (fr) * 1995-01-06 1996-07-11 Sibia Neurosciences, Inc. Peptide, analogue peptidique et analogue d'acide amine agissant comme inhibiteurs de protease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009838A1 (fr) * 1993-10-01 1995-04-13 Merrell Pharmaceuticals Inc. INHIBITEURS DE LA PRODUCTION DE PROTEINES DE β-AMYLOIDE
WO1996020725A2 (fr) * 1995-01-06 1996-07-11 Sibia Neurosciences, Inc. Peptide, analogue peptidique et analogue d'acide amine agissant comme inhibiteurs de protease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
XP002900183 *

Also Published As

Publication number Publication date
AU5354398A (en) 1998-06-10
HUP0001383A3 (en) 2001-11-28
CA2270876A1 (fr) 1998-05-28
BR9714358A (pt) 2000-03-21
NO992426L (no) 1999-06-30
NO992426D0 (no) 1999-05-20
WO1998022493A2 (fr) 1998-05-28
EP0942923A2 (fr) 1999-09-22
CN1237978A (zh) 1999-12-08
JP2001519769A (ja) 2001-10-23
IL129477A0 (en) 2000-02-29
TR199901132T2 (xx) 1999-08-23
ID22275A (id) 1999-09-23
NZ335157A (en) 2001-01-26
HUP0001383A1 (hu) 2001-05-28

Similar Documents

Publication Publication Date Title
WO1998022493A3 (fr) DERIVES DE N-(ARYL/HETEROARYL) AMINOACIDE, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET PROCEDES PERMETTANT D&#39;INHIBER LA LIBERATION DE PEPTIDE β AMYLOIDE ET/OU SA SYNTHESE A L&#39;AIDE DE CES COMPOSES
AU5249898A (en) N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
WO1998028268A3 (fr) CYCLOALKYLE, LACTAME ET COMPOSES ASSOCIES, COMPOSITIONS PHARMACEUTIQUES CONTENANT CES COMPOSES, ET PROCEDES D&#39;INHIBITION DE LA LIBERATION DU PEPTIDE β-AMYLOIDE ET/OU DE SA SYNTHESE AU MOYEN DE TELS COMPOSES
WO1998022494A3 (fr) METHODES ET COMPOSES DESTINES A INHIBER LA LIBERATION ET/OU LA SYNTHESE DU PEPTIDE β-AMYLOIDE
WO1998022441A3 (fr) ESTERS DE N-(ARYL/HETEROARYL) AMINOACIDE, COMPOSITIONS PHARMACEUTIQUES ET METHODES POUR INHIBER LA LIBERATION DU PEPTIDE β-AMYLOIDE ET/OU SA SYNTHESE
EA199900778A1 (ru) ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ И ИХ ИСПОЛЬЗОВАНИЕ ДЛЯ ИНГИБИРОВАНИЯ β-АМИЛОИДНОГО ПЕПТИДА
DE69912952D1 (en) Cyclosporine
CA2367017A1 (fr) Inhibiteurs de l&#39;enzyme impdh
EP1093372A4 (fr) COMPOSES D&#39;ACIDES AMINES CYCLIQUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET METHODES D&#39;INHIBITION DE LA LIBERATION DU PEPTIDE $g(b)-AMYLOIDE ET/OU DE SA SYNTHESE A L&#39;AIDE DE CES COMPOSES
ZA967379B (en) Meta-guanidine, urea, thiourea or azacyclic amino benzoic acid compounds and derivatives thereof.
WO2002047715A3 (fr) Compositions de cristaux de peptide
CA2379841A1 (fr) Derives de biphenyle, leur production et leur utilisation comme medicaments
CA2234610A1 (fr) Nouveaux derives d&#39;acide amine, procede de production correspondant et compositions pharmaceutiques contenant ces composes
CA2296036A1 (fr) Derives de dolastatine 15
HU9502843D0 (en) Pharmaceutical composition
BR0212787A (pt) Composto ou sal farmaceuticamente aceitável do mesmo, métodos de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto ou sal, e, composição farmacêutica
WO2002100818A3 (fr) Aminediols pour le traitement de la maladie d&#39;alzheimer
EP0296581A3 (fr) Dérivés 1,2-dicéto amino-acides comme inhibiteurs de la rénine
BR0115424A (pt) Composto, composição farmacêutica, métodos para inibir a liberação de peptìdeo beta-amilóide e/ou sua sìntese, para tratar a doença de alzheimer, para prevenir a doença de alzheimer, e para inibir o progresso da doença de alzheimer, processos para preparar o composto, e para preparar lactamas, e, uso do composto
CA2293714A1 (fr) Composes a base de cycloheptane benzpyrido servant d&#39;inhibiteurs de farnesyl proteine transferase
EP0985667A4 (fr) Nouveau derive de dihydropyridine
EP1123923A4 (fr) Derives de dihydropyridine et compositions medicamenteuses contenant ces derives
AU3494093A (en) S-lipophilic aliphatic carbonyl {n-mercaptoacyl-(amino acid or peptide)} compounds as antihypertensive agents
WO2001034639A3 (fr) COMPOSES CONTENANT DES β-ACIDES AMINES UTILES POUR INHIBER LA LIBERATION ET/OU LA SYNTHESE DU PEPTIDE β-AMYLOIDE
CA2208032A1 (fr) Derives d&#39;ester d&#39;amidinonaphtyle substitues

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97199776.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 335157

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 53543/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PV1999-1423

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 2270876

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 1998 523649

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/004527

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1019997004489

Country of ref document: KR

Ref document number: 1999/01132

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 1997950576

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997950576

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1019997004489

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV1999-1423

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1019997004489

Country of ref document: KR